The FDA has approved Eli Lilly’s oral obesity drug Foundayo, positioning it as a new contender in the weight-loss medication market alongside Novo Nordisk’s Wegovy, according to multiple sources. Foundayo, which will be available for shipment starting April 6 through LillyDirect, offers a convenient alternative for adults who are overweight or obese, with no injection required, as reported by Fast Company and NBC News Health.
Clinical trials for Foundayo demonstrated an average weight loss of 12.4%, with some studies indicating an average drop of 27.3 pounds at the highest dose, according to Fox News Health. The pill’s flexible daily dosing schedule allows patients to take it at any time without dietary restrictions, distinguishing it from current injectable options.
Despite the arrival of Foundayo, Novo Nordisk claims that Wegovy achieves greater weight loss—three percentage points more—and has a superior side effect profile that results in fewer treatment dropouts, Quartz reports. This highlights ongoing competition between the two companies in efficacy and tolerability within the GLP-1 weight management class.
The approval comes under a regulatory environment where the FDA faces increased scrutiny over advisory committee conflicts and the use of breakthrough device designations, as noted by STAT News. Foundayo’s launch expands patient options but also reflects evolving standards for drug approvals amid rising demand for obesity treatments.
Going forward, the market will be closely watched for how payers and providers respond to these oral GLP-1 therapies, especially around pricing and insurance coverage, which could impact patient access and market share. The introduction of Foundayo marks a significant development in obesity care that could reshape treatment dynamics between Eli Lilly and Novo Nordisk.
Eli Lilly
Foundayo
Novo Nordisk
Wegovy
FDA
